- Nano cap NephroGenex (NRX) announces that it has suspended its Phase 3 clinical trial of oral Pyridorin for the treatment of diabetic nephropathy, initiated a restructuring of operations and a strategic transaction (possible reverse merger) in order to better utilize its resources. It currently has $11.5M of quick assets on hand after paying off a $6.3M term loan.
- The company's Q4 and full-year 2015 earnings call scheduled for tomorrow has been cancelled.
- Previously: NephroGenex's late-stage study of Pyridorin in diabetic neuropathy to continue unchanged (Jan. 21)